Skip to main content

Advertisement

Table 2 Factors associated with recurrence-free survival

From: Adjuvant cytokine-induced killer cell immunotherapy for hepatocellular carcinoma: a propensity score-matched analysis of real-world data

  Univariable analysis Multivariable analysis
HR (95% CI) P value HR (95% CI) P value
Immunotherapy (Yes vs No) 0.42 (0.22–0.80) 0.008 0.38 (0.20–0.73) 0.004
Sex (male vs female) 0.93 (0.46–1.88) 0.85
Age (≥ 58 yrs vs < 58 yrs)a 0.94 (0.51–1.72) 0.84
Treatment modality (Resection vs RFA) 1.73 (0.76–3.95) 0.19
HCC stage (II vs I) 1.54 (0.83–2.87) 0.17
Number of HCC (≥ 3 vs < 3) 2.39 (0.57–9.95) 0.23
Size of HCC (≥ 2.75 cm vs < 2.75 cm)a 2.67 (1.39–5.11) 0.003 2.47 (1.25–4.90) 0.01
Cause of liver disease   0.51
 HBV infection 1 (reference)    
 HCV infection 0.78 (0.24–2.55)    
 Others 1.77 (0.30–10.62)    
Cirrhosis (Yes vs No) 1.45 (0.77–2.73) 0.25
α-fetoprotein (≥ 4 ng/mL vs < 4 ng/mL)a 1.93 (1.03–3.61) 0.04 1.12 (0.54–2.31) 0.76
PIVKA-II (≥ 20 mAU/mL vs < 20 mAU/mL)a 0.74 (0.40–1.36) 0.34
Aspartate aminotransferase (≥ 30 IU/L vs < 30 IU/L)a 1.99 (1.04–3.79) 0.04 1.62 (0.81–3.24) 0.17
Alanine aminotransferase (≥ 27 IU/L vs < 27 IU/L)a 1.60 (0.86–2.97) 0.14
Alkaline phosphatase (≥ 83 IU/L vs < 83 IU/L)a 1.73 (0.92–3.27) 0.09
Albumin (≥ 4.2 g/dL vs < 4.2 g/dL)a 0.36 (0.19–0.68) 0.001 0.51 (0.25–1.04) 0.06
Total bilirubin (≥ 0.7 mg/dL vs < 0.7 mg/dL)a 1.40 (0.74–2.64) 0.31
Prothrombin time, INR (≥ 1.09 vs < 1.09)a 1.56 (0.83–2.90) 0.17
Creatinine (≥ 0.85 mg/dL vs < 0.85 mg/dL)a 0.82 (0.44–1.50) 0.52
Platelet (≥ 173 mm3 vs < 173 mm3)a 0.69 (0.36–1.32) 0.27
Lymphocyte to monocyte ratio (≥ 4.36 vs < 4.36)a 0.47 (0.25–0.89) 0.02 0.87 (0.40–1.90) 0.72
  1. aContinuous variables are divided according to their median values
  2. RFA radiofrequency ablation, HCC hepatocellular carcinoma, HBV hepatitis B virus, HCV hepatitis C virus, PIVKA-II protein induced by vitamin K absence-II, INR international normalized ratio, HR hazard ratio